quidditastherapeutics.comCrawled Oct 27, 2026
Quidditas raised €2.62 million to advance its genome editing technology, expanding research capacity and scaling up treatments for rare diseases, protein bioproduction, and stem cell research.
Co-founded QUIDDITAS Therapeutics in 2021 to develop a disruptive genome recombination technology. Holds a PhD in Biotechnologies/Genetics from a co-thesis program between Université de Paris and Massachusetts General Hospital/Harvard Medical School, and an engineering degree in Biotechnologies from Ecole de Biologie Industrielle. His management training is from the HEC Paris (Challenge +). More than 10 years of experience in molecular designs for sequencing and genome editing technologies.
Quidditas Therapeutics developed an alternative technology which permits an absolute genetic recombination with a large scope of applications.
Quidditas Therapeutics raises €2.62 million to develop its next-generation genome editing technology, addressing current limitations in gene therapy. The Liège-based startup, founded in 2022, aims to enhance precision editing to unlock broader therapeutic applications. This funding accelerates research and development of its proprietary platform.
May 2025StartupMafia - News from startup industry -News article
Quidditas secures €2.62 million in funding to advance its **GREAT genome-editing platform**, a pioneering technology in biotech. The investment supports further development of its editing capabilities, positioning the company at the forefront of genetic research innovations. The platform targets precise, scalable genome modifications for potential applications in medicine and agriculture.
May 2025Tech Funding NewsNews article
Quidditas secures **€2.62 million** in funding to advance its **genome-editing technology**. The capital will support expanded research capacity and scaling efforts for the company’s pioneering approach.
May 2025menafn.comNews article